@article{open3141,
          volume = {21},
          number = {5},
           month = {March},
          author = {Mitra Pirhaghi and Fatemeh Mamashli and Faezeh Moosavi-Movahedi and Payam Arghavani and Ahmad Amiri and Bagher Davaeil and Mahya Mohammad-Zaheri and Zahra Mousavi-Jarrahi and Deepak Sharma and Ulo Langel and Daniel Erik Otzen and Ali Akbar Saboury},
            note = {The copyright of this article belongs to ACS },
           title = {Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases},
       publisher = {ACS},
            year = {2024},
         journal = {MOLECULAR PHARMACEUTICS},
           pages = {2097--2117},
        keywords = {Alzheimer?s disease (AD); Parkinson?s disease (PD); cell-penetrating peptides; central nervous system disorders; drug delivery; peptide-nanoparticle conjugate.},
             url = {http://crdd.osdd.net/open/3141/},
        abstract = {Currently, one of the most significant and rapidly growing unmet medical challenges is the treatment of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). This challenge encompasses the imperative development of efficacious therapeutic agents and overcoming the intricacies of the blood-brain barrier for successful drug delivery. Here we focus on the delivery aspect with particular emphasis on cell-penetrating peptides (CPPs), widely used in basic and translational research as they enhance drug delivery to challenging targets such as tissue and cellular compartments and thus increase therapeutic efficacy. The combination of CPPs with nanomaterials such as nanoparticles (NPs) improves the performance, accuracy, and stability of drug delivery and enables higher drug loads. Our review presents and discusses research that utilizes CPPs, either alone or in conjugation with NPs, to mitigate the pathogenic effects of neurodegenerative diseases with particular reference to AD and PD.}
}